Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ventyx Biosciences, Inc. (VTYX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.00-0.65 (-3.49%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.65
Open18.91
Bid10.00 x 900
Ask18.32 x 900
Day's Range16.72 - 19.21
52 Week Range16.32 - 26.00
Volume135,928
Avg. Volume292,222
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

    ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences: Event: 4th Annual Evercore ISI HealthCONx ConferenceLocation: Virt

  • GlobeNewswire

    Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

    Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3 million in gross proceeds, including full exercise of unde

  • Barrons.com

    Lumen Technologies and Ventyx Biosciences Stock See Action From Activist Investors

    Southeastern Asset Management reported a large stake in communications company Lumen. Third Point revealed a new position in clinical-stage biopharmaceutical company Ventyx.

Advertisement
Advertisement